These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 14511240)

  • 21. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.
    Lin F; Fukuoka Y; Spicer A; Ohta R; Okada N; Harris CL; Emancipator SN; Medof ME
    Immunology; 2001 Oct; 104(2):215-25. PubMed ID: 11683962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity.
    Miwa T; Zhou L; Tudoran R; Lambris JD; Madaio MP; Nangaku M; Molina H; Song WC
    Mol Immunol; 2007 Jan; 44(1-3):139-46. PubMed ID: 16887189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
    Kim DD; Miwa T; Song WC
    J Immunol; 2006 Oct; 177(8):5558-66. PubMed ID: 17015743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
    Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
    Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.
    Pritchard MT; McMullen MR; Stavitsky AB; Cohen JI; Lin F; Edward Medof M; Nagy LE
    Gastroenterology; 2007 Mar; 132(3):1117-1126. PubMed ID: 17383432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells.
    Moutabarrik A; Nakanishi I; Namiki M; Hara T; Matsumoto M; Ishibashi M; Okuyama A; Zaid D; Seya T
    Lymphokine Cytokine Res; 1993 Jun; 12(3):167-72. PubMed ID: 7688580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-beta and TNF-alpha.
    Cocuzzi ET; Bardenstein DS; Stavitsky A; Sundarraj N; Medof ME
    Curr Eye Res; 2001 Aug; 23(2):86-92. PubMed ID: 11840345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phorbol esters increase synthesis of decay-accelerating factor, a phosphatidylinositol-anchored surface protein, in human endothelial cells.
    Bryant RW; Granzow CA; Siegel MI; Egan RW; Billah MM
    J Immunol; 1990 Jan; 144(2):593-8. PubMed ID: 1688581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells.
    Andoh A; Kinoshita K; Rosenberg I; Podolsky DK
    J Immunol; 2001 Oct; 167(7):3887-93. PubMed ID: 11564806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement activation induces the expression of decay-accelerating factor on human mesangial cells.
    Shibata T; Cosio FG; Birmingham DJ
    J Immunol; 1991 Dec; 147(11):3901-8. PubMed ID: 1719094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis.
    Fukuta D; Miyagawa S; Yamada M; Matsunami K; Kurihara T; Shirasu A; Hattori H; Shirakura R
    Xenotransplantation; 2003 Mar; 10(2):132-41. PubMed ID: 12588646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells.
    Cosio FG; Shibata T; Rovin BH; Birmingham DJ
    Kidney Int; 1994 Oct; 46(4):986-92. PubMed ID: 7532249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decay-accelerating factor but not CD59 limits experimental immune-complex glomerulonephritis.
    Bao L; Haas M; Minto AW; Quigg RJ
    Lab Invest; 2007 Apr; 87(4):357-64. PubMed ID: 17259999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF.
    Li B; Sallee C; Dehoff M; Foley S; Molina H; Holers VM
    J Immunol; 1993 Oct; 151(8):4295-305. PubMed ID: 7691944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Leung VW; Yun S; Botto M; Mason JC; Malik TH; Song W; Paixao-Cavalcante D; Pickering MC; Boyle JJ; Haskard DO
    Am J Pathol; 2009 Oct; 175(4):1757-67. PubMed ID: 19729477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex.
    Fecke W; Long J; Richards A; Harrison R
    Xenotransplantation; 2002 Mar; 9(2):97-105. PubMed ID: 11897002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway.
    Grehan JF; Levay-Young BK; Fogelson JL; François-Bongarçon V; Benson BA; Dalmasso AP
    J Immunol; 2005 Aug; 175(3):1903-10. PubMed ID: 16034134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis.
    Lin F; Emancipator SN; Salant DJ; Medof ME
    Lab Invest; 2002 May; 82(5):563-9. PubMed ID: 12003997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
    Bjørge L; Jensen TS; Matre R
    Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.